Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | EIF4EBP1 | Q13541 | 11/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | DUT | P33316 | 3/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16632595 | 0.94 | L3MBTL1 (0.44) | L3MBTL1EIF4EBP1SLC6A4DUTKCNH2 | |
| SCHEMBL16632412 | 0.94 | L3MBTL1 (0.49) | L3MBTL1EIF4EBP1SLC6A4CYP1A2CYP2C19 | |
| SCHEMBL16632610 | 0.93 | L3MBTL1 (0.40) | L3MBTL1EIF4EBP1DUT | |
| SCHEMBL16632484 | 0.89 | L3MBTL1 (0.40) | L3MBTL1DUT | |
| SCHEMBL16632282 | 0.89 | L3MBTL1 (0.47) | L3MBTL1EIF4EBP1SLC6A4CYP1A2CYP2C19 | |
| SCHEMBL16632420 | 0.87 | L3MBTL1 (0.47) | L3MBTL1EIF4EBP1DUT | |
| SCHEMBL16634453 | 0.86 | L3MBTL1 (0.39) | L3MBTL1EIF4EBP1SLC6A4DUT | |
| SCHEMBL16116697 | 0.85 | L3MBTL1 (0.53) | L3MBTL1EIF4EBP1SLC6A4CYP1A2CYP2C19 | |
| SCHEMBL14871830 | 0.85 | L3MBTL1 (0.53) | L3MBTL1EIF4EBP1SLC6A4CYP1A2CYP2C19 | |
| SCHEMBL14871847 | 0.81 | L3MBTL1 (0.58) | L3MBTL1EIF4EBP1CYP1A2CYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382245-B2 | Compounds and methods for treating HIV infections | YALE UNIVERSITY (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | POLM, POLRMT, DHFR | L3MBTL1 879/4885EIF4EBP1 4140/4885SLC6A4 4266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.